Marshall Wace LLP Lowers Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Marshall Wace LLP lessened its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,017,539 shares of the biotechnology company's stock after selling 698,006 shares during the quarter. Marshall Wace LLP owned approximately 0.67% of Heron Therapeutics worth $1,557,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Heron Therapeutics by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock worth $411,000 after buying an additional 154,487 shares in the last quarter. Principal Financial Group Inc. increased its position in Heron Therapeutics by 456.5% in the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock worth $204,000 after purchasing an additional 84,205 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Heron Therapeutics in the fourth quarter worth $208,000. Congress Park Capital LLC increased its position in Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after purchasing an additional 477,417 shares during the last quarter. Finally, Barclays PLC increased its position in Heron Therapeutics by 29.8% in the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock worth $434,000 after purchasing an additional 50,109 shares during the last quarter. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Trading Up 1.3 %

HRTX stock opened at $2.33 on Tuesday. The stock has a market cap of $354.93 million, a PE ratio of -12.94 and a beta of 1.39. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The company has a 50-day moving average price of $2.13 and a 200 day moving average price of $1.79.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to analysts' expectations of $37.37 million. Sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on HRTX shares. Needham & Company LLC restated a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.